Omalizumab
- Generic Name
- Omalizumab
- Brand Names
- Xolair, Omlyclo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 242138-07-4
- Unique Ingredient Identifier
- 2P471X1Z11
- Background
Omalizumab, manufactured by Genentech, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids . Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated . In September 2018, a new prefil...
- Indication
This drug is an anti-IgE antibody indicated for:
- Associated Conditions
- Chronic Idiopathic Urticaria, Moderate Asthma, Severe Asthma
- Associated Therapies
- -
Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 31
- Registration Number
- NCT02388997
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Yale University
- Target Recruit Count
- 9
- Registration Number
- NCT02266355
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Omalizumab in Severe and Refractory Solar Urticaria
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 10
- Registration Number
- NCT02262130
- Locations
- 🇫🇷
CHRU de Lille, Lille, France
🇫🇷Dermatology department, Hôpital Saint-Louis, Paris, France
🇫🇷CHU de Grenoble, Grenoble, France
Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02191072
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Urticaria Facticia Treatment With Omalizumab (UFO)
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 61
- Registration Number
- NCT02169115
- Locations
- 🇩🇪
University Dermatology Freiburg, Freiburg, Germany
🇩🇪Dermatology University Mainz, Mainz, Germany
OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 314
- Registration Number
- NCT02161562
- Locations
- 🇵🇦
Novartis Investigative Site, Panama, Panama
Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT02118987
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 17
- Registration Number
- NCT02023151
- Locations
- 🇺🇸
Johns Hopkins Asthma & Allergy Center, Baltimore, Maryland, United States
Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2015-12-22
- Target Recruit Count
- 630
- Registration Number
- NCT01976208
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳Chinese PLA Fuzhou General Hospital of Nanjing Military Command, Fuzhou, China
🇨🇳The Second Affiliated Hospital of Zhejiang University, Hangzhou, China
A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 806
- Registration Number
- NCT01922037
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Chest Medicine Consultants, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.